232 related articles for article (PubMed ID: 6580171)
1. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
[TBL] [Abstract][Full Text] [Related]
2. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Wehmeier A; Fricke S; Scharf RE; Schneider W
Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
[TBL] [Abstract][Full Text] [Related]
3. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders.
Berild D; Hasselbalch H; Knudsen JB
Scand J Clin Lab Invest; 1987 Sep; 47(5):497-501. PubMed ID: 3477851
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of haemorrhagic and thrombotic events in myeloproliferative disorders: a retrospective study of 108 patients.
Grossi A; Rosseti S; Vannucchi AM; Rafanelli D; Ferrini PR
Clin Lab Haematol; 1988; 10(2):167-75. PubMed ID: 3416575
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
[TBL] [Abstract][Full Text] [Related]
6. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
Murphy S; Davis JL; Walsh PN; Gardner FH
Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
[TBL] [Abstract][Full Text] [Related]
7. Uncontrolled thrombocytosis in chronic myeloproliferative disorders.
Kessler CM; Klein HG; Havlik RJ
Br J Haematol; 1982 Jan; 50(1):157-67. PubMed ID: 6976793
[TBL] [Abstract][Full Text] [Related]
8. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
10. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
Tangün Y
Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
[No Abstract] [Full Text] [Related]
11. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.
Michiels JJ; Berneman ZN; Schroyens W; Van Vliet HH
Platelets; 2004 Mar; 15(2):67-84. PubMed ID: 15154599
[TBL] [Abstract][Full Text] [Related]
12. Platelet 5-hydroxytryptamine transport and storage in myeloproliferative disorders.
Cortellazzo S; Viero P; Buczko W; Barbui T; de Gaetano G
Scand J Haematol; 1985 Feb; 34(2):146-51. PubMed ID: 3856312
[TBL] [Abstract][Full Text] [Related]
13. [Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
Meschengieser SS; Woods AI; Schattner MA; Lazzari MA
Medicina (B Aires); 1981; 41 Suppl():267-73. PubMed ID: 6954340
[No Abstract] [Full Text] [Related]
14. Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count.
Gremmel T; Gisslinger B; Gisslinger H; Panzer S
Transl Res; 2018 Oct; 200():35-42. PubMed ID: 30012347
[TBL] [Abstract][Full Text] [Related]
15. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
16. Platelet function in patients with high platelet counts.
Ginsburg AD
Ann Intern Med; 1975 Apr; 82(4):506-11. PubMed ID: 1054537
[TBL] [Abstract][Full Text] [Related]
17. Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders.
Meschengieser S; Blanco A; Woods A; Maugeri N; Fernandez J; Dupont J; Lazzari MA
Thromb Res; 1987 Nov; 48(3):311-9. PubMed ID: 3501618
[TBL] [Abstract][Full Text] [Related]
18. [Clinical conference: Histaaminemia in myeloproliferative syndromes].
Cadiou M; Ruff F; Meunier F; Attalah N; Bernadou A; Zittoun R; Parrot JL; Bousser J
Nouv Rev Fr Hematol; 1975; 15(2):261-9. PubMed ID: 126436
[No Abstract] [Full Text] [Related]
19. Clinical significance of beta-thromboglobulin in patients with high platelet count.
Fabris F; Randi ML; Casonato A; Dal Bo Zanon R; Bonvicini P; Girolami A
Acta Haematol; 1984; 71(1):32-8. PubMed ID: 6197855
[TBL] [Abstract][Full Text] [Related]
20. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
Brodsky I; Kahn SB; Ross EM; Petkov G
Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
